Diagnostics

Bausch Health heads to a key finance conference to address investor concerns over its massive debt, upcoming patent cliffs, and future strategic direction.

A new health tech company has assembled a star-studded scientific board to back its AI-powered dementia prevention app. But can it deliver on its promise?

A second real-world study finds an FDA-approved device brings significant relief to over 80% of tinnitus patients, offering new hope for millions.

Nearly half of UK couples struggle with hearing loss, eroding intimacy. A new campaign reveals why a hearing check may be more romantic than any gift.

A new genomics tracker reveals the fragmented adoption of precision cancer care across the EU-5, highlighting critical barriers and strategic opportunities.

LEX Diagnostics' newly FDA-cleared VELO system delivers lab-quality PCR results for flu & COVID in under 10 minutes, set to revolutionize point-of-care testing.

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

Researchers have developed a robust, wearable sensor that detects dangerous ammonia gas through both color and electronics, promising a new era of smart PPE.

Blue Cross and MassChallenge award five startups $50k each to solve critical health disparities, from endometriosis diagnosis to language access in hospitals.

Often dismissed as a simple stomach bug, norovirus is a serious threat. Health experts reveal why hand sanitizer fails and what you must do to stay safe.

A new diagnostic tool for interstitial lung disease receives FDA Fast Track, promising earlier, more accurate detection of deadly lung inflammation.

A new integrated test from NeoGenomics aims to slash diagnostic delays and streamline complex tumor profiling, promising faster, smarter cancer treatment.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.

A new report shows 40% of ANZ firms never assess skin cancer risk, despite 84% seeing it as a duty of care, exposing a massive legal and health liability.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

Bio-Techne promotes Steve Crouse to lead its high-growth Diagnostics and Spatial Biology unit, signaling a strategic focus on innovation after a key divestiture.

Basketball icons partner with the Prostate Cancer Foundation in a new push for early screening, aiming to save lives and combat racial health disparities.

A surge in healthcare job applications offers a prime opportunity, but new data reveals a critical bottleneck preventing companies from turning interest into hires.

Katherine Stueland’s honor underscores a major shift in healthcare, as genomic screening and AI promise to end the diagnostic odyssey for rare diseases.